Analysis of diagnostic timelines during the pandemic and reflections on health system resilience
The Covid-19 pandemic has profoundly changed the organization and delivery of health care services around the world. In particular, many medical specialties not directly involved in the management of the virus, such as urology, have been significantly impacted due to reorganization of resources, health restrictions, and patients' fear of accessing hospital facilities. This has led to diagnostic delays, particularly in urologic oncologic diseases, potentially affecting patients' prognosis.
Reorganization of health services
During the acute phase of the pandemic (March 2020-June 2021), many hospitals converted urological departments to Covid units or drastically reduced non-emergency outpatient and diagnostic activities. Elective surgery has been suspended or postponed, and instrumental investigations (such as prostate biopsies, ultrasound scans, cystoscopies, and CT scans) have experienced long wait times.
A study conducted in Italy found that more than 50% of urology centers reported a cessation of nonemergency activities, with an 80% reduction in first outpatient visits.
A study conducted in Italy found that more than 50% of urology centers reported a cessation of nonemergency activities, with an 80% reduction in first outpatient visits.
Clinical consequences
Delayed access to diagnosis has had a significant impact on urologic oncology diseases, in particular:
- Prostate cancer: reduced screening with PSA and delay in prostate biopsies.
- Bladder cancer: delays in diagnostic cystoscopies have led to later stage diagnoses.
A European multicenter study found that 21% of urologic oncology patients had worsening tumor stage at diagnosis, which can be directly attributed to pandemic delays.
- Prostate cancer: reduced screening with PSA and delay in prostate biopsies.
- Bladder cancer: delays in diagnostic cystoscopies have led to later stage diagnoses.
A European multicenter study found that 21% of urologic oncology patients had worsening tumor stage at diagnosis, which can be directly attributed to pandemic delays.
Quantitative data on timing
In the Italian context, a retrospective study showed that the average time between symptom onset and final diagnosis increased by more than 3 months compared with the pre-pandemic period. In particular:
- Prostate carcinoma: 45 to 92 days.
- Bladder carcinoma: 30 to 68 days.
These timelines increase the risk of tumor progression and complicate the treatment approach.
- Prostate carcinoma: 45 to 92 days.
- Bladder carcinoma: 30 to 68 days.
These timelines increase the risk of tumor progression and complicate the treatment approach.
Reflections on health system resilience
Despite the difficulties, the urological system has shown adaptability and resilience:
- Telemedicine: many centers have implemented virtual consultations for follow-up and management of chronic patients.
- Priority triage: algorithms have been developed to identify cases to be treated urgently, preserving timeliness in high-risk cancers.
- Post-pandemic recovery: starting in 2022, waiting lists have been gradually disposed of with extraordinary surgical sessions and intensified diagnostic activities.
These strategies, although not sufficient to entirely close the diagnostic gap, have been an important response in containing the clinical consequences of delay.
To cope with these difficulties, one possible solution is voluntary diagnostics, that is, the possibility for people to undergo checkups on their own, even outside the traditional pathways of the public health system.
A current example of a resilient response to diagnostic difficulties is the introduction of Urine24, the first urine cytology test available online. Urine24 offers noninvasive, reliable, and accessible diagnosis directly at home, thus breaking down logistical barriers and potential delays in diagnosis. The kit is easily purchased online, allows home urine collection for three days, and delivers the report via e mail in a few days. In addition, a partnership with LILT Florence promotes its use in the context of prevention, with solidarity purposes as well.
- Telemedicine: many centers have implemented virtual consultations for follow-up and management of chronic patients.
- Priority triage: algorithms have been developed to identify cases to be treated urgently, preserving timeliness in high-risk cancers.
- Post-pandemic recovery: starting in 2022, waiting lists have been gradually disposed of with extraordinary surgical sessions and intensified diagnostic activities.
These strategies, although not sufficient to entirely close the diagnostic gap, have been an important response in containing the clinical consequences of delay.
To cope with these difficulties, one possible solution is voluntary diagnostics, that is, the possibility for people to undergo checkups on their own, even outside the traditional pathways of the public health system.
A current example of a resilient response to diagnostic difficulties is the introduction of Urine24, the first urine cytology test available online. Urine24 offers noninvasive, reliable, and accessible diagnosis directly at home, thus breaking down logistical barriers and potential delays in diagnosis. The kit is easily purchased online, allows home urine collection for three days, and delivers the report via e mail in a few days. In addition, a partnership with LILT Florence promotes its use in the context of prevention, with solidarity purposes as well.
Conclusion
The Covid-19 pandemic has highlighted the fragilities of the health care system, particularly in ensuring diagnostic continuity for non-Covid diseases. In urology, delays have had a measurable impact, especially in oncology. However, the adoption of new technologies, organizational flexibility and recovery of clinical activities show resilience that can be enhanced in future scenarios. It is now essential to invest in more dynamic care models that can protect timely access to care even in crisis situations.
